May 19 2022

Classification of the active ingredient almotriptan

Risk level in pregnancy: This medicine is classified as Category C.

There are no controlled studies on the use of this substance during pregnancy. It has a very limited number of data in pregnant patients exposed to almotriptan. Animal studies show no direct or indirect harmful effects on pregnancy, embryonal or fetal development, parturition or postnatal development.

Update 18.07.2009

Meaning of category C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.